Intradermal influenza vaccination of healthy adults using a new microinjection system: a 3-year randomised controlled safety and immunogenicity trial.
about
Long-term immunogenicity of the influenza vaccine at reduced intradermal and full intramuscular doses among healthy young adultsThe immunogenicity of the intradermal injection of seasonal trivalent influenza vaccine containing influenza A(H1N1)pdm09 in COPD patients soon after a pandemic.New technologies for influenza vaccines.Microneedle and mucosal delivery of influenza vaccines.Stabilization of influenza vaccine enhances protection by microneedle delivery in the mouse skinChanges in human Langerhans cells following intradermal injection of influenza virus-like particle vaccines.Intradermal vaccination with influenza virus-like particles by using microneedles induces protection superior to that with intramuscular immunization.Laser vaccine adjuvant for cutaneous immunization.Dose sparing enabled by skin immunization with influenza virus-like particle vaccine using microneedles.Intradermal delivery of vaccines: potential benefits and current challenges.Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone®) administered by intradermal and intramuscular route in healthy adults.A micro-sterile inflammation array as an adjuvant for influenza vaccines.Effective and lesion-free cutaneous influenza vaccinationImmunosenescence and Challenges of Vaccination against Influenza in the Aging Population.Assessment of acceptability and usability of new delivery prototype device for intradermal vaccination in healthy subjects.Current evidence on intradermal influenza vaccines administered by Soluvia™ licensed micro injection system.Micro-fractional Epidermal Powder Delivery for Skin Vaccination.Microneedles for drug and vaccine deliveryPhase 4 randomized trial of intradermal low-antigen-content inactivated influenza vaccine versus standard-dose intramuscular vaccine in HIV-1-infected adults.Intanza (®) 9 µg intradermal seasonal influenza vaccine for adults 18 to 59 years of age.Nine μg intradermal influenza vaccine and 15 μg intramuscular influenza vaccine induce similar cellular and humoral immune responses in adults.Acceptance of intradermal inactivated influenza vaccines among hospital staff following 2 seasonal vaccination campaignsInfluenza vaccines: unmet needs and recent developments.Immunogenicity and safety of Intanza(®)/IDflu(®) intradermal influenza vaccine in South Korean adults: a multicenter, randomized trial.MF59-adjuvanted vaccine: a safe and useful tool to enhance and broaden protection against seasonal influenza viruses in subjects at risk.Clinical studies assessing immunogenicity and safety of intradermally administered influenza vaccines.Intanza(®): a new intradermal vaccine for seasonal influenza.Intradermal influenza vaccine and new devices: a promising chance for vaccine improvement.Fluzone(®) Intradermal vaccine: a promising new chance to increase the acceptability of influenza vaccination in adults.A meta-analysis of intradermal versus intramuscular influenza vaccines: immunogenicity and adverse events.Microneedle patches for vaccine delivery.The role of microneedles for drug and vaccine delivery.Biomedical applications of microneedles in therapeutics: recent advancements and implications in drug delivery.Microneedle patches for vaccination in developing countries.Improved influenza vaccination in the skin using vaccine coated microneedles.Acceptance and opinions of Intanza/IDflu intradermal influenza vaccine in the Czech Republic and Turkey.Acceptance and safety of the intradermal influenza vaccine among the elderly in Italy: an on-field national study.
P2860
Q30352137-2CF1F242-DEE5-449E-BC03-7098125F2985Q30387788-34437BA3-BCDA-4D92-BD5B-9AAF06B8139BQ30411859-D2F6E542-77BB-449C-A50C-2EBA3F0D3D2CQ30418015-1A8C2C00-F8EA-4A47-831B-B3CADEAA58D8Q33506637-3566276D-643A-4BEF-9B1E-6E40D48740DAQ33682225-B4F1942D-DC8F-431E-837A-CE7EBC351BB6Q33964159-99059E1F-5AFB-4674-B7FA-1DDBC0AC8B6BQ34046148-6DEDCCA2-1275-45B2-AF77-01A245278328Q34288194-02BC92A7-14D0-4FC9-B8C1-C4F6D08FCE30Q34601669-0A147435-7DAD-450E-A788-483B99A5D082Q35148060-576C4962-CB50-459B-AD72-D069FC8CA83BQ35208463-9186F7B9-F4D9-431B-918C-450F16B786E0Q35549338-800F6935-6852-4483-90A2-52EF12461F6FQ35874111-3FB66160-9D8C-4ABE-B6EE-6DB7D9506B73Q35886486-6BE85543-1B4C-44EA-A7C7-B6A7CE9379B6Q35952784-866B4531-9C73-42E7-BA3D-E38874C564D3Q35989230-17D40A12-A6C1-4217-9168-5DDF7F3CFC2FQ36164749-4F52D3C9-10BF-44FE-B3C0-1C9BCD5F62A6Q36552868-FCA92639-1E3D-4C41-B3F6-3D3986DFC3DAQ36887912-518664D9-B13F-4009-BC09-790083FB088FQ37159662-056833CD-3D9F-4824-A824-75B72424E8AAQ37320174-6D93F7C8-107F-4C7B-8780-609FBE9AC8E0Q37518273-4D682DF5-E9C5-4CCE-9287-C311F3990E7BQ37530388-BC68D671-6C8C-4A78-B441-E192A73EBAD0Q37706610-235A8E0C-47F3-4DA2-A885-EE0B0CA2E3BBQ37780548-70070B7A-5BB6-4CE1-8EFD-81644340D02DQ37812124-A7999846-7511-47A3-8AFD-F46164771008Q37836900-FC4691AB-FF8D-4508-824E-DA617182AE28Q37965721-497196E7-F63F-4C41-BB56-92D4E61E7CF7Q38043033-19EDB0E7-48BA-4BED-BBBD-1E5FE8D9720CQ38178693-05EF03B9-90E2-4F3A-BF87-EC97742BE350Q38229145-5B0690BB-C779-4D16-A1A5-79974F93481DQ38630763-34787E5B-A48A-41D4-8925-5F37E2732153Q38646712-6DF6B1DB-88D5-4FD5-94A0-35381FB00E8AQ42602202-0E9AC0AA-661F-45DD-A25F-17E9A4CE5EC3Q43172242-E82940DE-AD10-494A-AC14-2BCC26076D3AQ45785920-68E7D086-CFBC-4FD3-A175-471218028ACD
P2860
Intradermal influenza vaccination of healthy adults using a new microinjection system: a 3-year randomised controlled safety and immunogenicity trial.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 02 April 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Intradermal influenza vaccinat ...... fety and immunogenicity trial.
@en
Intradermal influenza vaccinat ...... fety and immunogenicity trial.
@nl
type
label
Intradermal influenza vaccinat ...... fety and immunogenicity trial.
@en
Intradermal influenza vaccinat ...... fety and immunogenicity trial.
@nl
prefLabel
Intradermal influenza vaccinat ...... fety and immunogenicity trial.
@en
Intradermal influenza vaccinat ...... fety and immunogenicity trial.
@nl
P2093
P2860
P356
P1433
P1476
Intradermal influenza vaccinat ...... fety and immunogenicity trial.
@en
P2093
Alvydas Laiskonis
Arvydas Ambrozaitis
Camille Salamand
Etienne Demanet
Françoise Weber
Jiri Beran
Narseta Mickuviene
Patrick Bacart
Paul Van Belle
Stephane Heijmans
P2860
P2888
P356
10.1186/1741-7015-7-13
P407
P577
2009-04-02T00:00:00Z